In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
about
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic optionsInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadStenotrophomonas maltophilia: an emerging global opportunistic pathogenClinical experimentation with aerosol antibiotics: current and future methods of administration.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?Mucin Binding Reduces Colistin Antimicrobial Activity.In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.Levofloxacin-proliposomes: opportunities for use in lung tuberculosis.Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update.MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.Inhaled aztreonam lysine: an evidence-based review.Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosisLevofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections.In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.Novel Glycopolymer Eradicates Antibiotic- and CCCP-Induced Persister Cells in
P2860
Q26782924-E45C5608-2599-44F6-B0AC-184AD0981D40Q26822988-25B37196-B3E1-42C6-804E-87F98365E2FFQ26995336-6DBC87A2-FC66-43C5-AB74-6AA9A4438E7EQ30448377-6BA13708-B9E0-4C8D-BB77-142C1B972F9AQ34297656-43C5ECD7-04D4-49EB-99FA-306EF5D8F4ADQ34309282-B7F07A78-7227-4188-93A3-6645C6168E74Q35004983-B0E61C0F-41C2-4DD3-B94F-7D0AC8045F19Q35143793-BC99E16D-5E66-4AF9-B821-DF5B8A3BF971Q36076096-E955851F-E624-41F2-8E38-E77457452EB5Q36308077-8A6C34C8-802D-4AE6-9A33-1B0F82E3AD2AQ37327834-2F937F33-D553-4B55-83E3-A89AC940E3ABQ37915360-4FA10E81-49D3-4198-AC4E-9675A8B2CCD5Q38061971-D06323FD-980C-46CD-9F39-8C7528C90636Q38132897-6A09BA12-D858-4038-B691-F3D43124D885Q38170953-3872BC33-571A-44B5-B8F6-9870BD5447BAQ38270626-0CB8EEC8-5007-4C67-B5D0-11EAC7B79640Q38378454-EE171129-763C-4679-BB12-AE213681A9D3Q40652733-6219CEA3-7E9C-41A6-8347-9F01F4A4E4A9Q53806089-9D57BD20-E302-46DA-B0BA-C6134359D81DQ58801856-16A38669-7B60-4E44-B0C8-977DC28A0C46
P2860
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@en
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@nl
type
label
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@en
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@nl
prefLabel
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@en
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@nl
P2093
P2860
P356
P1476
In vitro pharmacodynamics of l ...... infection in cystic fibrosis.
@en
P2093
David C Griffith
Jane L Burns
Michael N Dudley
Olga Lomovskaya
Paula King
P2860
P304
P356
10.1128/AAC.00248-09
P407
P577
2009-10-05T00:00:00Z